TY - JOUR T1 - Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study JF - European Respiratory Journal JO - Eur Respir J SP - 1211 LP - 1214 DO - 10.1183/13993003.00051-2015 VL - 46 IS - 4 AU - Swanny Perrin AU - David Montani AU - Caroline O'Connell AU - Sven Günther AU - Barbara Girerd AU - Laurent Savale AU - Christophe Guignabert AU - Olivier Sitbon AU - Gerald Simonneau AU - Marc Humbert AU - Marie-Camille Chaumais Y1 - 2015/10/01 UR - http://erj.ersjournals.com/content/46/4/1211.abstract N2 - In the scientific and medical community, it is recognised that exposure to certain drugs could promote the development of pulmonary arterial hypertension (PAH). These drugs, with a “class effect” (amphetamine-like) or not (dasatinib), are prescribed for serious (dasatinib, interferons) or moderate (benfluorex) pathologies and do not induce PAH in all patients [1–9]. As a result, assessment of drug history exposure from PAH patients has become essential for providing optimal disease management [10].More studies are needed to measure nasal decongestant exposure in patients with pulmonary arterial hypertension http://ow.ly/OFxs8We acknowledge the French pulmonary hypertension pharmacovigilance network, VIGIAPATH, supported by the French national agency for medicines and health products safety (Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)) as well as the French patient association HTAPFrance. ER -